How does the gut microbiome influence immune checkpoint blockade therapy?

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Immune checkpoint blockade (ICB) therapies offer revolutionary cancer treatment but benefit only a third of patients.
• Emerging research highlights the gut microbiome's critical role in ICB therapeutic success.
• Studies show gut flora composition and diversity impact cancer treatment outcomes in mice and humans.

Purpose of the Study:

• To review the importance of the gut microbiome in ICB therapy.
• To propose hypotheses for the gut flora's impact on ICB efficacy.
• To describe potential mechanisms, such as bacterial translocation, enhancing antitumor responses.

Main Methods:

• Review of high-impact studies on gut microbiome and ICB therapy.
• Analysis of existing data on bacterial composition and treatment outcomes.
• Hypothetical mechanism development for bacterial adjuvant effects.

Main Results:

• Gut microbiome composition, presence, and diversity directly influence ICB treatment outcomes.
• Antibiotic use near cancer treatment can negatively affect therapeutic success.
• Specific bacteria may promote greater therapeutic benefit.

Conclusions:

• The gut microbiome is a crucial factor in ICB therapy efficacy.
• Further research is needed to identify beneficial bacteria and their mechanisms.
• Manipulating the gut microbiome could improve cancer treatment outcomes.